UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): November 7, 2014
(Exact Name of Registrant as Specified in Charter)
|
Nevada
|
333-155318
|
20-5337455
|
|
(State or other Jurisdiction
of Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S. Employer Identification No.)
|
3888 E. Mexico Ave., Suite 202
Denver, CO 80210
(Address of principal executive offices) (Zip Code)
(303) 309-0105
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On November 7, 2014, CannLabs, Inc. (the “Company”) issued a press release announcing that CannLabs – Nevada, Inc. had received licensing approval for a new laboratory in North Las Vegas, Nevada. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Forward Looking Statements
Certain statements contained herein are “forward-looking statements.” These statements include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. All statements other than statements of historical facts included or incorporated by reference in this Current Report on Form 8-K, including without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues, projected costs and plans and objective of management for future operations, are forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” or “believes” or the negative thereof or any variation there on or similar terminology or expressions.
We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to: our ability to raise additional capital, the absence of any operating history or revenue, our ability to attract and retain qualified personnel, market acceptance of our platform, our limited experience in a relatively new industry, regulatory and competitive developments, intense competition with larger companies, general economic conditions, as well as other factors set forth under the caption “Risk Factors” in our Current Report on Form 8-K dated June 12, 2014 filed with the Securities and Exchange Commission on June 13, 2014 and subsequently amended on August 15, 2014, September 12, 2014, and October 10, 2014.
All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. Except as required by law, we assume no duty to update or revise our forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
| |
|
| (d) |
Exhibits |
| |
|
| 99.1 |
Press release of CannLabs, Inc., dated as of November 7, 2014 |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
| |
CANNLABS, INC.
|
| |
|
|
Dated: November 7, 2014
|
/s/ Scott McPherson |
| |
Scott McPherson |
| |
Chief Financial Officer
|
Exhibit 99.1
 |
www.cannlabs.com |
FOR IMMEDIATE RELEASE:
William Livermore
Public Relations
917-620-0774
William.livermore@cannlabs.com
www.cannlabs.com
CANNLABS APPROVED TO OPEN ITS LARGEST CANNABIS
LABORATORY IN NEVADA
Investment to Exceed 1 Million Dollars in North Las Vegas
Denver, Colo., November 7, 2014 -- CannLabs, Inc. (OTCQB: CANL), the leading provider of proprietary cloud based analytics, and scientific testing methodologies relating to cannabis, today announced both state and local approval for an independent testing facility in Nevada to analyze medical cannabis. The license has been granted to CannLabs – Nevada, Inc. (“CannLabs – NV”).
The laboratory will be based in North Las Vegas, which is in the heart of Nevada’s “Cannabis Greenbelt”. The state-of-the-art laboratory will have capabilities to provide all state-mandated tests including potency profiles, microbiological contaminates, heavy metal analysis and pesticide and residual solvent screenings. Additionally, CannLabs-NV, utilizing over 4 years of proprietary analytics will offer a broad spectrum of consultative services; formulation consultation, analytics evaluation and operational consultation, including offering assistance to operators with the remediation of contaminated grows and identifying manufacturing issues.
“With the granting of the license to CannLabs – NV, CannLabs Inc. enters one of the largest and most rapidly growing medical marijuana markets in the country. CannLabs-NV is the Health and Safety checkpoint in the seed-to-sale pipeline, assuring the well being of the patients of Nevada,” said Mark Mirken, Chief Executive Officer of CannLabs. “Early projections indicate that the matured market for medical cannabis testing in Nevada could exceed $15 million. We estimate the lab will capture upwards of 30% of the market by the end of the first year of full market maturity,” added Mirken.
“As Nevada moves forward with the cultivation and sale of medical marijuana, our top priority is protecting the health and safety of consumers. That’s why I’m pleased to welcome CannLabs’ expertise and professionalism to Southern Nevada. Having visited their Denver facility, I am confident the opening of their laboratory and research center here will bring the highest standards of quality and safety to our state’s developing medical cannabis industry,” said Rep. Dina Titus (NV-01).
Under an agreement with Carbon Bonds Holdings, a wholly owned subsidiary of CannLabs, Inc., the company provides administrative services and licenses proprietary software to CannLabs – Nevada, Inc. CannLabs-NV is planning to begin construction in early 2015; the project will take approximately 6 months to complete and cost in excess of $1 million. When completed, the 8,000 sq. ft. facility will be in close proximity to an estimated 1.5 million sq.ft. of projected cannabis production. Located at the highly visible corner of N. Las Vegas Blvd and Cheyenne Ave, with convenient access to Interstate 15, the project’s completion is timed to match the testing demand generated from Nevada’s first large scale cannabis crops.
3888 E. Mexico Avenue, Suite 202 | Denver, CO 80210 | 303.309.0105
|
www.cannlabs.com |
The testing laboratory is licensed by the city of North Las Vegas and the Nevada Division of Public and Behavioral Health. Nevada has some of the most stringent quality control standards in the nation and adheres to the American Herbal Pharmacopoeia® (AHP) guidelines for permissible limits of contaminants.
ABOUT CANNLABS
CannLabs, Inc., is a respected authority and advisor to commercial, governmental and educational entities focused on the Cannabis industry. The company leverages its propriety scientific, testing processes, cloud-based business intelligence and data/analytics as well as consulting services to garner revenues from legalized Cannabis states and their constituents.
Through Carbon Bond Holdings Inc. and the state certified labs it has relationships with, CannLabs delivers best practices around products, services and business intelligence focused on the Cannabis industry.
CannLabs customers include states that currently have legalized medical or recreational Cannabis along with their associated growers, dispensaries, manufacturers of edibles, and residential consumers seeking information on cannabis.
For more information visit www.cannlabs.com.
Safe Harbor Statement
All statements herein other than statements of historical facts are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Such statements are not guarantees of future performance and are subject to known and unknown risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements. Such factors include, but are not limited to, our ability to raise additional capital, our limited operating history and revenue, our ability to attract and retain qualified personnel, our ability to develop new services, market acceptance of our services, legislative, regulatory and competitive developments in our industry, general economic conditions, as well as other factors set forth in our filings with the SEC.
3888 E. Mexico Avenue, Suite 202 | Denver, CO 80210 | 303.309.0105
|
www.cannlabs.com |
CONTACT:
Company
William Livermore
Public Relations
917-620-0774
william.livermore@cannlabs.com
www.cannlabs.com
Investor Relations
Matthew Selinger
Senior Vice President – MZ North America
949-298-4319
mselinger@mzgroup.us
www.mzgroup.us
3888 E. Mexico Avenue, Suite 202 | Denver, CO 80210 | 303.309.0105
CannLabs (CE) (USOTC:CANL)
Historical Stock Chart
From May 2024 to Jun 2024
CannLabs (CE) (USOTC:CANL)
Historical Stock Chart
From Jun 2023 to Jun 2024
